Journal
BJU INTERNATIONAL
Volume 125, Issue 2, Pages 197-205Publisher
WILEY
DOI: 10.1111/bju.14915
Keywords
non-muscle invasive bladder cancer; guidelines; immunotherapy; bacillus Calmette-Guerin; #bladdercancer
Categories
Ask authors/readers for more resources
Non-muscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with frequent recurrences and risk of progression. Risk-stratified treatment and surveillance protocols are often used to guide management. In 2017, BJUI reviewed guidelines on NMIBC from four major organizations: the American Urological Association/Society of Urological Oncology, the European Association of Urology, the National Comprehensive Cancer Network, and the National Institute for Health and Care Excellence. The present update will review major changes in the guidelines and broadly summarize new recommendations for treatment of NMIBC in an era of bacillus Calmette-Guerin shortage and immense novel therapy development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available